AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated ...

A new BLA for Dato-DXd targets EGFR-mutated NSCLC, following withdrawal of a previous application based on TROPION-Lung01 trial data. The new submission is supported by phase 2 TROPION-Lung05 trial ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

The FDA is expected to decide on treatments for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine.

The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...